Article successfully added.

CyFlow™ CD255 PE

CyFlow™ CD255 PE
Alternative Name: TWEAK
Antibody: Yes
Antigen: CD255
Application: Flow cytometry
Clonality: monoclonal
Clone: CARL-1
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Apoptosis, Immunophenotyping
Format/Fluorochrome: PE
Isotype: IgG3
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AS153004

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Quantity 100 tests Volume 1.0 mL Immunogen Human CD255-transfected 2PK-3 cells... more
Close menu
CyFlow™ CD255 PE
Quantity100 tests
Volume1.0 mL
ImmunogenHuman CD255-transfected 2PK-3 cells
Background InformationCD255 (TWEAK; TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 (TWEAK R). On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumors. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma‑stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6; 192(9):1373‑80. < PMID: 11067885 > | Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J Immunol. 2003 Jan 1; 170(1):341‑8. < PMID: 12496418 > | Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF‑kappaB2 p100 processing and long lasting NF‑kappaB activation. J Biol Chem. 2003 Sep 19; 278(38):36005‑12. < PMID: 12840022 > | Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor‑like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec; 146(3):540‑9. < PMID: 17100776 > | Brown SA, Ghosh A, Winkles JA: Full‑length, membrane‑anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF‑kappaB pathway. J Biol Chem. 2010 Jun 4; 285(23):17432‑41. < PMID: 20385556 > | Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan; 2(1):103‑108. < PMID: 22977477 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet